Research programme: non-antibacterial macrolides - Melinta Therapeutics

Drug Profile

Research programme: non-antibacterial macrolides - Melinta Therapeutics

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Optimer Pharmaceuticals
  • Developer Cempra Pharmaceuticals; Melinta Therapeutics
  • Class Macrolides
  • Mechanism of Action Histone deacetylase modulators; LHRH receptor antagonists; Motilin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase Unknown Chronic obstructive pulmonary disease
  • No development reported Cancer; Diabetic gastroparesis; Psoriasis

Most Recent Events

  • 06 Nov 2017 Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic gastroparesis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top